188 related articles for article (PubMed ID: 38673967)
41. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
42. Targeted anticancer prodrug therapy using dextran mediated enzyme-antibody conjugate and β-cyclodextrin-curcumin inclusion complex.
Roozbehi S; Dadashzadeh S; Mirshahi M; Sadeghizadeh M; Sajedi RH
Int J Biol Macromol; 2020 Oct; 160():1029-1041. PubMed ID: 32479931
[TBL] [Abstract][Full Text] [Related]
43. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
44. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
45. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
Sun Y; Wang X; Zhou Q; Lu Y; Zhang H; Chen Q; Zhao M; Su S
Oncol Rep; 2015 Jan; 33(1):338-46. PubMed ID: 25370743
[TBL] [Abstract][Full Text] [Related]
46. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.
Lee J; Hahm ER; Singh SV
Carcinogenesis; 2010 Nov; 31(11):1991-8. PubMed ID: 20724373
[TBL] [Abstract][Full Text] [Related]
47. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS.
Xu P; Yin Q; Shen J; Chen L; Yu H; Zhang Z; Li Y
Int J Pharm; 2013 Sep; 454(1):21-30. PubMed ID: 23830941
[TBL] [Abstract][Full Text] [Related]
48. Cyclodextrin encapsulation enabling the anticancer repositioning of disulfiram: Preparation, analytical and in vitro biological characterization of the inclusion complexes.
Benkő BM; Tóth G; Moldvai D; Kádár S; Szabó E; Szabó ZI; Kraszni M; Szente L; Fiser B; Sebestyén A; Zelkó R; Sebe I
Int J Pharm; 2024 May; 657():124187. PubMed ID: 38697585
[TBL] [Abstract][Full Text] [Related]
49. Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells.
Coker-Gurkan A; Celik M; Ugur M; Arisan ED; Obakan-Yerlikaya P; Durdu ZB; Palavan-Unsal N
Amino Acids; 2018 Aug; 50(8):1045-1069. PubMed ID: 29770869
[TBL] [Abstract][Full Text] [Related]
50. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas.
Hutzen B; Friedman L; Sobo M; Lin L; Cen L; De Angelis S; Yamakoshi H; Shibata H; Iwabuchi Y; Lin J
Int J Oncol; 2009 Oct; 35(4):867-72. PubMed ID: 19724924
[TBL] [Abstract][Full Text] [Related]
51. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
53. Carvacrol/β-cyclodextrin inclusion complex inhibits cell proliferation and migration of prostate cancer cells.
Trindade GGG; Thrivikraman G; Menezes PP; França CM; Lima BS; Carvalho YMBG; Souza EPBSS; Duarte MC; Shanmugam S; Quintans-Júnior LJ; Bezerra DP; Bertassoni LE; Araújo AAS
Food Chem Toxicol; 2019 Mar; 125():198-209. PubMed ID: 30615955
[TBL] [Abstract][Full Text] [Related]
54. Curcumin "Drug" Stabilized in Oxidovanadium(IV)-BODIPY Conjugates for Mitochondria-Targeted Photocytotoxicity.
Bhattacharyya U; Kumar B; Garai A; Bhattacharyya A; Kumar A; Banerjee S; Kondaiah P; Chakravarty AR
Inorg Chem; 2017 Oct; 56(20):12457-12468. PubMed ID: 28972748
[TBL] [Abstract][Full Text] [Related]
55. Molecular recognition and enhancement of aqueous solubility and bioactivity of CD437 by β-cyclodextrin.
Mishur RJ; Griffin ME; Battle CH; Shan B; Jayawickramarajah J
Bioorg Med Chem Lett; 2011 Jan; 21(2):857-60. PubMed ID: 21185186
[TBL] [Abstract][Full Text] [Related]
56. The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells.
Boonrao M; Yodkeeree S; Ampasavate C; Anuchapreeda S; Limtrakul P
Arch Pharm Res; 2010 Jul; 33(7):989-98. PubMed ID: 20661707
[TBL] [Abstract][Full Text] [Related]
57. Development of curcumin-loaded gemini surfactant nanoparticles: Synthesis, characterization and evaluation of anticancer activity against human breast cancer cell lines.
Karimpour M; Feizi MAH; Mahdavi M; Krammer B; Verwanger T; Najafi F; Babaei E
Phytomedicine; 2019 Apr; 57():183-190. PubMed ID: 30776589
[TBL] [Abstract][Full Text] [Related]
58. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.
Kim JE; Kim HS; Shin YJ; Lee CS; Won C; Lee SA; Lee JW; Kim Y; Kang JS; Ye SK; Chung MH
Exp Mol Med; 2008 Oct; 40(5):514-22. PubMed ID: 18985009
[TBL] [Abstract][Full Text] [Related]
59. Stoichiometrically Governed Curcumin Solid Dispersion and Its Cytotoxic Evaluation on Colorectal Adenocarcinoma Cells.
Mohamed JMM; Alqahtani A; Ahmad F; Krishnaraju V; Kalpana K
Drug Des Devel Ther; 2020; 14():4639-4658. PubMed ID: 33173275
[TBL] [Abstract][Full Text] [Related]
60. 10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation.
Zhao Q; Bi Y; Zhong J; Li X; Guo J; Liu YX; Pan LR; Tan Y; Deng ZS; Yu XJ
Acta Pharmacol Sin; 2021 May; 42(5):791-800. PubMed ID: 32868906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
